FI3474822T3 - Brinsidofoviirin formulaatioita - Google Patents
Brinsidofoviirin formulaatioitaInfo
- Publication number
- FI3474822T3 FI3474822T3 FIEP17737695.1T FI17737695T FI3474822T3 FI 3474822 T3 FI3474822 T3 FI 3474822T3 FI 17737695 T FI17737695 T FI 17737695T FI 3474822 T3 FI3474822 T3 FI 3474822T3
- Authority
- FI
- Finland
- Prior art keywords
- concentration
- brincidofovir
- arginine
- mannitol
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355844P | 2016-06-28 | 2016-06-28 | |
| US201662394665P | 2016-09-14 | 2016-09-14 | |
| US201762446213P | 2017-01-13 | 2017-01-13 | |
| US201762465053P | 2017-02-28 | 2017-02-28 | |
| US201762507397P | 2017-05-17 | 2017-05-17 | |
| US201762512825P | 2017-05-31 | 2017-05-31 | |
| PCT/US2017/039804 WO2018005676A1 (en) | 2016-06-28 | 2017-06-28 | Formulations of brincidofovir |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3474822T3 true FI3474822T3 (fi) | 2025-08-15 |
Family
ID=59313330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17737695.1T FI3474822T3 (fi) | 2016-06-28 | 2017-06-28 | Brinsidofoviirin formulaatioita |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20170368082A1 (https=) |
| EP (2) | EP4295853A3 (https=) |
| JP (3) | JP6878473B2 (https=) |
| CN (4) | CN114569547A (https=) |
| AU (2) | AU2017290703B2 (https=) |
| DK (1) | DK3474822T3 (https=) |
| ES (1) | ES3037596T3 (https=) |
| FI (1) | FI3474822T3 (https=) |
| PL (1) | PL3474822T3 (https=) |
| PT (1) | PT3474822T (https=) |
| WO (1) | WO2018005676A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962829B1 (en) | 2013-11-15 | 2015-02-24 | Chimerix, Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
| AU2017290703B2 (en) * | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN114073772A (zh) * | 2020-08-18 | 2022-02-22 | 上海市公共卫生临床中心 | 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途 |
| CN114558022B (zh) * | 2022-02-16 | 2023-11-17 | 华中农业大学 | 布林西多福韦在制备抗伪狂犬病毒药物中的应用 |
| CN114732821A (zh) * | 2022-04-24 | 2022-07-12 | 华中农业大学 | 西多福韦的前药在制备防治非洲猪瘟药物中的应用 |
| JP7417339B1 (ja) * | 2023-08-07 | 2024-01-18 | シンバイオ製薬株式会社 | アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療 |
| AU2024353056A1 (en) * | 2023-09-29 | 2026-04-23 | Symbio Pharmaceuticals Limited | Brincidofovir for treatment of multiple sclerosis |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747954C (en) | 1999-12-03 | 2014-02-25 | The Regents Of The University Of California | Phosphonate compounds |
| JP4136340B2 (ja) * | 2000-08-18 | 2008-08-20 | 武田薬品工業株式会社 | 注射剤 |
| US8642577B2 (en) | 2005-04-08 | 2014-02-04 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
| EP2842559A3 (en) | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
| AU2008246195B2 (en) * | 2007-04-27 | 2014-06-05 | Emergent Biodefence Operations Lansing Llc | Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates |
| JP2011116658A (ja) | 2008-03-13 | 2011-06-16 | Chemo-Sero-Therapeutic Research Inst | 豚萎縮性鼻炎用薬剤の製造方法 |
| WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
| CA2770282A1 (en) | 2009-08-03 | 2011-02-10 | Chimerix, Inc. | Composition and methods of treating viral infections and viral induced tumors |
| CA2779473C (en) | 2009-10-30 | 2016-08-16 | Chimerix, Inc. | Methods of treating viral associated diseases |
| WO2011066684A1 (zh) * | 2009-12-03 | 2011-06-09 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| US20110263536A1 (en) | 2010-04-22 | 2011-10-27 | Chimerix, Inc. | Methods of Treating Orthopox Virus Infections and Associated Diseases |
| WO2012031045A2 (en) | 2010-08-31 | 2012-03-08 | Chimerix, Inc. | Phosphonate ester derivatives and methods of synthesis thereof |
| US20140303092A1 (en) * | 2011-10-26 | 2014-10-09 | Chimerix, Inc | Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection |
| WO2013163509A1 (en) | 2012-04-27 | 2013-10-31 | Chimerix, Inc. | A method of mitigating virus associated end-organ damage |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| US8962829B1 (en) * | 2013-11-15 | 2015-02-24 | Chimerix, Inc. | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
| AU2017290703B2 (en) * | 2016-06-28 | 2023-03-30 | Emergent Biodefense Operations Lansing Llc | Formulations of brincidofovir |
-
2017
- 2017-06-28 AU AU2017290703A patent/AU2017290703B2/en active Active
- 2017-06-28 JP JP2018568195A patent/JP6878473B2/ja active Active
- 2017-06-28 WO PCT/US2017/039804 patent/WO2018005676A1/en not_active Ceased
- 2017-06-28 CN CN202210134248.1A patent/CN114569547A/zh active Pending
- 2017-06-28 PT PT177376951T patent/PT3474822T/pt unknown
- 2017-06-28 DK DK17737695.1T patent/DK3474822T3/da active
- 2017-06-28 EP EP23195544.4A patent/EP4295853A3/en active Pending
- 2017-06-28 CN CN201780040478.9A patent/CN109475497A/zh active Pending
- 2017-06-28 FI FIEP17737695.1T patent/FI3474822T3/fi active
- 2017-06-28 PL PL17737695.1T patent/PL3474822T3/pl unknown
- 2017-06-28 US US15/636,393 patent/US20170368082A1/en not_active Abandoned
- 2017-06-28 ES ES17737695T patent/ES3037596T3/es active Active
- 2017-06-28 EP EP17737695.1A patent/EP3474822B1/en active Active
- 2017-06-28 CN CN202410393564.XA patent/CN118416082A/zh active Pending
- 2017-06-28 CN CN202411127002.7A patent/CN119139329A/zh active Pending
-
2019
- 2019-12-20 US US16/722,699 patent/US20200138835A1/en not_active Abandoned
-
2021
- 2021-04-28 JP JP2021075612A patent/JP7221485B2/ja active Active
-
2022
- 2022-07-25 US US17/872,921 patent/US12485131B2/en active Active
-
2023
- 2023-01-18 JP JP2023005643A patent/JP7407984B2/ja active Active
- 2023-06-28 AU AU2023204117A patent/AU2023204117B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7407984B2 (ja) | 2024-01-04 |
| AU2017290703A1 (en) | 2018-12-13 |
| ES3037596T3 (en) | 2025-10-03 |
| EP3474822B1 (en) | 2025-07-09 |
| US12485131B2 (en) | 2025-12-02 |
| CN118416082A (zh) | 2024-08-02 |
| JP2019519570A (ja) | 2019-07-11 |
| EP4295853A2 (en) | 2023-12-27 |
| EP4295853A3 (en) | 2024-03-06 |
| AU2017290703B2 (en) | 2023-03-30 |
| AU2023204117B2 (en) | 2025-03-20 |
| JP2021143178A (ja) | 2021-09-24 |
| CN109475497A (zh) | 2019-03-15 |
| US20230210873A1 (en) | 2023-07-06 |
| CA3024886A1 (en) | 2018-01-04 |
| JP6878473B2 (ja) | 2021-05-26 |
| EP3474822A1 (en) | 2019-05-01 |
| JP2023033538A (ja) | 2023-03-10 |
| PT3474822T (pt) | 2025-08-21 |
| US20170368082A1 (en) | 2017-12-28 |
| CN114569547A (zh) | 2022-06-03 |
| US20200138835A1 (en) | 2020-05-07 |
| PL3474822T3 (pl) | 2025-11-03 |
| WO2018005676A1 (en) | 2018-01-04 |
| AU2023204117A1 (en) | 2023-07-13 |
| JP7221485B2 (ja) | 2023-02-14 |
| CN119139329A (zh) | 2024-12-17 |
| DK3474822T3 (da) | 2025-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3474822T3 (fi) | Brinsidofoviirin formulaatioita | |
| JP2019519570A5 (https=) | ||
| JP2023033538A5 (https=) | ||
| HRP20211224T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| Smith et al. | Macromolecular (pro) drugs in antiviral research | |
| JP2008540499A5 (https=) | ||
| RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
| RU2012105310A (ru) | Фукозиллактоза в качестве неусвояемого олигосахарида, идентичного грудному молоку, с новой функциональной пользой | |
| CY1119839T1 (el) | Στερεες μορφες δοσεως μπενταμουστινης | |
| HRP20250266T1 (hr) | Nukleotid hemi-sulfat sol za liječenje virusa hepatitisa c | |
| Chang et al. | Hepatitis B virus with primary resistance to adefovir | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| CO6341567A2 (es) | Vacuna contra el virus de papiloma humano | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| NZ588655A (en) | Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin | |
| RU2010113984A (ru) | Применение врр-в в качестве терапевтического средства | |
| JP2016534062A5 (https=) | ||
| Liang et al. | Therapeutic applications of Spirulina against human pathogenic viruses. | |
| RU2013125339A (ru) | Фармацевтическая композиция для лечения гепатита с | |
| WO2011138489A1 (es) | Uso de hidrolizados de caseínas como antivirales | |
| US20140030364A1 (en) | Antiviral compositions comprising ethanol extract of tetracera scandens and use thereof | |
| Monavari et al. | the study of antiviral effects of glycyrrihza glabra extract on HSV | |
| De Clercq | Vesicular stomatitis virus (VSV) as a paradigm for predicting antiviral activity against Ebola virus (EBOV) | |
| RU2018123711A (ru) | Композиции для внутривенного введения |